Alzheimer's Disease Trial, Recruiting NCT07041450 Sponsor: MoCA Clinic and Institute Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07041450
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been referred to the MoCA Clinic, either as a new patient or as an existing patient who has not been seen there for more than one year.
  • People who are experiencing memory or thinking difficulties, or who have concerns about their memory or thinking.
  • People who are able to understand the purpose and risks of the study and are willing to give their formal consent to participate.
  • People who have someone in their life — such as a family member, friend, or carer — who has regular and close enough contact with them to accurately describe their thinking and daily functioning, is reachable by phone, is available for the length of the study, and is willing to attend at least one in-person visit at the MoCA Clinic.

Who may not be able to join:

  • People who have already been diagnosed with a condition other than Alzheimer's disease that explains their memory or thinking difficulties — for example, substance misuse, stroke-related conditions, Lewy body dementia, frontotemporal dementia, or a recent head injury.
  • People who have donated blood (one unit) within one month before the study screening appointment.
  • People who are unable to complete the essential parts of the study — for example, due to significant vision problems, severe kidney disease, or ongoing kidney treatment (confirm with trial site).
  • People who are already taking part in another clinical trial for Alzheimer's disease at the time of screening.
  • People who the lead researcher or the MoCA Clinic considers unsuitable for the study for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ziad Nasreddine, MD, MoCA Clinic

Phone: 5147585033

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
MoCA Clinic and Institute
Registry
ClinicalTrials.gov
Start date
14 March 2025
Est. completion
14 December 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Time to diagnosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov